Holen Sie sich die Stockscreener-App
4.25
11.17%
0.40
Schlusskurs vom Vortag:
$3.85
Offen:
$4.3
24-Stunden-Volumen:
5.65M
Relative Volume:
23.42
Marktkapitalisierung:
$2.24M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.00507
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
-11.93%
1M Leistung:
-28.43%
6M Leistung:
-92.65%
1J Leistung:
-93.86%
1-Tages-Spanne:
$4.18
$7.47
1-Wochen-Bereich:
$3.50
$7.47
52-Wochen-Spanne:
$3.50
$220.25
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Firmenname
Biodexa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BDRX | 4.25 | 2.24M | 644.60K | -9.87M | -9.02M | -837.96 |
| VRTX | 449.84 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.58 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.39 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
ADR Ratio Change - Markets Insider
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Biodexa secures full access to cancer research grant - Investing.com
BDRX Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News
Balance Sheet Breakdown: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
Financial Metrics Check: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios for Trailing Twelve Months - The Dwinnex
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Are Smart Investors Making the Right Decision? Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks
The time has not yet come to remove your chips from the table: Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
eRapa shows promise in Phase 2 for FAP treatment, Biodexa reveals - Investing.com
BDRX’s Stock Market Adventure: -73.47% YTD Growth Amidst Volatility - The InvestChronicle
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan
Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM - Quantisnow
Midatech Pharma PLC Announces Business Update - Quantisnow
Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development - Quantisnow
Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective - Quantisnow
Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):